Prostate
MiCheck® Prostate
Clinically Significant Prostate Cancer Risk Assessment
An advancement in risk assessment for clinically significant prostate cancer—helping reduce unnecessary biopsies and support confident monitoring decisions.
PSA alone can't distinguish clinically significant prostate cancer from benign conditions, inflammation, or low-grade disease that doesn't require intervention—and that ambiguity sends men to biopsy who may not need one. MiCheck® Prostate uses a proprietary, proven algorithm combining multiple FDA-approved biomarkers with the patient's age to produce a single risk score for clinically significant prostate cancer (csPCa), giving you and your patient a number worth reasoning from together.
Clinical Performance
Validated in the MiCheck-01 Prospective US Trial
- 95% Sensitivity—correctly identifies patients at increased risk for csPCa
- 62% Specificity—correctly identifies patients not at increased risk for csPCa
- 96% NPV (GS ≥3+4)—high confidence in not missing increased-risk disease
- 99% NPV (GS ≥4+3)—high confidence in not missing increased-risk disease
- 53% PPV—confidence in correctly identifying increased-risk disease
- 0.85 AUC—strong overall discriminative accuracy
- Specificity, NPV (GS ≥3+4) and PPV: Shore ND, Polikarpov DM, Pieczonka CM, et al. Substitution of DRE result with patient age results in enhanced test performance for MiCheck® Prostate blood test for clinically significant prostate cancer. Manuscript in preparation. 2026.
- Sensitivity, NPV (GS ≥4+3), AUC and biopsy reduction: Shore ND, Polikarpov DM, Pieczonka CM, et al. Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer. Urologic Oncology: Seminars and Original Investigations. 2023;41(11):454.e9–454.e16. https://doi.org/10.1016/j.urolonc.2023.08.005
Key Benefits
-
An Advancement in csPCa Risk Assessment
Clinical performance in the MiCheck-01 trial that outperforms PSA alone in head-to-head validation.
-
Reduces Unnecessary Biopsies
Better risk stratification means up to 50% of unnecessary biopsies could be avoided, sparing patients an invasive procedure they didn't need.
-
Age-Adjusted for Earlier Use
A “normal” PSA isn't normal for every age. MiCheck® Prostate uses age-adjusted thresholds starting as early as men 40–49 (PSA ≥1 ng/mL), 50–59 (≥2 ng/mL), and 60+ (≥3 ng/mL).
-
Beyond PSA Alone
A multi-biomarker, age-adjusted algorithm provides clinical depth that a single PSA value cannot match.
-
Supports Shared Decision-Making
Reported as a percentage risk patients can actually understand—giving both physician and patient something concrete to reason from.
-
Published, Peer-Reviewed Evidence
Findings published in Urologic Oncology (2020, 2023), giving clinicians a documented evidence base to stand behind.
View publications & studies
Test Specifications
| Test Name | MiCheck® Prostate |
|---|---|
| Purpose | Clinically significant prostate cancer (csPCa) risk assessment |
| Methodology | Proprietary algorithm combining multiple FDA-approved biomarkers and patient age |
| Specimen Type | Blood draw |
| Use Case | Patients with elevated PSA or other concerning findings; biopsy decision support and active surveillance |
| Target Population | Men being evaluated for possible prostate cancer |
| Availability | Available nationwide, with different setups and platforms tailored to each state's requirements. Run in your own lab (limitations may apply on a case-by-case basis), or send out to SoftCell Labs, a Doc Lab-owned company. |
Blood Hormone Testing
Blood hormone testing that runs on the same platform as MiCheck® Prostate, so your lab can expand its testing without adding new equipment.
Let's talk
Better Biopsy Decisions Start Here
MiCheck® Prostate provides the risk assessment you need to help patients make informed decisions. Let's discuss how it fits your urology practice.